AccurEdit Therapeutics' LNP-based In Vivo Gene Editing Product ART001 Obtained Orphan Drug Designation from the FDA
AccurEdit Therapeutics today announced that its innovative in vivo gene editing product, ART001, has obtained Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA).
Fierce Biotech1d
Carisma winds down operations, lays off 95% of remaining staff
After a year of stripping back its head count and pipeline, Carisma Therapeutics is now cutting down to the bone and laying ...
Pharmaceutical Technology on MSN9d
FDA approves IND application for Everest’s cancer vaccine
EVM14 is the first messenger RNA (mRNA) therapeutic vaccine developed internally by the company to gain this approval. Its ...
Taiwan News8d
AccurEdit Therapeutics' LNP-based In Vivo Gene Editing Product ART001 Obtained Orphan Drug Designation from the FDA
It is currently the first and only LNP-based in vivo gene editing product worldwide that has cleared an IND in both China and the United States. It was also China's first LNP-based in vivo gene ...